Oral inhibitor shows clinical activity in poor-prognosis AML

An oral targeted drug has shown encouraging activity and tolerable side effects in patients with treatment-resistant or relapsed acute myelogenous leukemia — a poor-prognosis group with few options — report investigators from Dana-Farber Cancer Institute and M.D. Anderson Cancer Center. —> Read More Here


Leave a Reply

Your email address will not be published. Required fields are marked *